Join us for an insightful webinar brought to you by Takeda Pharmaceuticals on "Managing inhibitors in Congenital Hemophilia with Inhibitors (CHaWI) patients undergoing surgery." Our panel of hematology experts, Dr. Prakas Kumar Mandal, Dr. Suresh Hanagavadi, and Dr. NV Ramaswamy, will cover essential strategies, challenges, and advancements in pre-surgical and perioperative care to ensure optimal outcomes for CHaWI patients. Enhance your understanding of this critical aspect of hemophilia care and engage with leading specialists in the field. Register now to secure your spot in this informative session.

Inhibitor management in CHaWI patients undergoing surgery

Extended half-life (EHL) recombinant factor VIII drugs promise excellent prophylaxis by reducing dose frequency, enhancing compliance, and improving quality of life while maintaining safety and efficacy. This session will provide a detailed overview of the rationale for developing EHL coagulation factors and their use in the treatment of haemophilia A, with a focus on the indications, efficacy, and safety of the existing EHL-FVIII products.

Emerging role of EHL FVIII in Hemophilia A Mx with better clinical outcomes

Professor, Department of Hematology | Nil Ratan Sircar Medical college and Hospital, Kolkata

Dr. Prakas Kumar Mandal

2

350

6.9k

4.5

Sessions Taken

169

4.6

194

4.5